Kynam Capital Management, LP Biocryst Pharmaceuticals Inc Transaction History
Kynam Capital Management, LP
- $1.28 Billion
- Q2 2024
A detailed history of Kynam Capital Management, LP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Kynam Capital Management, LP holds 8,826,710 shares of BCRX stock, worth $74.4 Million. This represents 4.25% of its overall portfolio holdings.
Number of Shares
8,826,710
Previous 6,527,491
35.22%
Holding current value
$74.4 Million
Previous $33.2 Million
64.51%
% of portfolio
4.25%
Previous 3.48%
Shares
8 transactions
Others Institutions Holding BCRX
# of Institutions
257Shares Held
173MCall Options Held
397KPut Options Held
444K-
Black Rock Inc. New York, NY20MShares$168 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.8MShares$158 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.6MShares$106 Million1.06% of portfolio
-
State Street Corp Boston, MA9.35MShares$78.8 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY8.14MShares$68.6 Million1.06% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.57B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...